###begin article-title 0
###xml 69 77 <span type="species:ncbi:9606">Patients</span>
Osteoclasts Are Active in Bone Forming Metastases of Prostate Cancer Patients
###end article-title 0
###begin p 1
Conceived and designed the experiments: IR PD. Performed the experiments: IR EG AG CF. Analyzed the data: IR PD RF. Contributed reagents/materials/analysis tools: LB LD AT AD GI. Wrote the paper: IR PD RF.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 214 221 214 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
Bone forming metastases are a common and disabling consequence of prostate cancer (CaP). The potential role of osteoclast activity in CaP bone metastases is not completely explained. In this study, we investigated ex vivo whether the osteolytic activity is present and how it is ruled in CaP patients with bone forming metastases.
###end p 3
###begin title 4
Methodology
###end title 4
###begin p 5
###xml 464 472 464 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
Forty-six patients affected by newly diagnosed CaP and healthy controls were enrolled. At diagnosis, 37 patients had a primary tumour only, while 9 had primary tumour and concomitant bone forming metastases. In all patients there was no evidence of metastasis to other non-bone sites. For all patients and controls we collected blood and urinary samples. We evaluated patients' bone homeostasis; we made peripheral blood mononuclear cell (PBMC) cultures to detect in vitro osteoclastogenesis; we dosed serum expression of molecules involved in cancer induced osteoclatogenesis, such as RANKL, OPG, TNF-alpha, DKK-1 and IL-7. By Real-Time PCR, we quantified DKK-1 and IL-7 gene expression on micro-dissected tumour and healthy tissue sections.
###end p 5
###begin title 6
Principal Findings
###end title 6
###begin p 7
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
###xml 488 496 <span type="species:ncbi:9606">patients</span>
CaP bone metastatic patients showed bone metabolism disruption with increased bone resorption and formation compared to non-bone metastatic patients and healthy controls. The CaP PBMC cultures showed an enhanced osteoclastogenesis in bone metastatic patients, due to an increase of RANKL/OPG ratio. We detected increased DKK-1 serum levels and tissue gene expression in patients compared to controls. IL-7 resulted high in patients' sera, but its tissue gene expression was comparable in patients and controls.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
We demonstrated ex vivo that osteoclastogenesis is an active mechanism in tumour nesting of bone forming metastatic cancer and that serum DKK-1 levels are increased in CaP patients, suggesting to deeply investigate its role as tumour marker.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 82 85 82 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Keller1">[1]</xref>
###xml 222 225 222 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Bubendorf1">[2]</xref>
###xml 326 329 326 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Keller1">[1]</xref>
###xml 868 871 868 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Logothetis1">[3]</xref>
###xml 78 81 <span type="species:ncbi:9606">men</span>
###xml 175 178 <span type="species:ncbi:9606">men</span>
Prostate cancer (CaP) is the second leading cause of cancer-related deaths in men [1]. A typical feature of CaP is the ability to metastatize to the bone, as more than 80% of men who died for CaP developed bone metastases [2]. Growth of CaP within bone promotes primarily osteoblastic lesions with underlying osteolytic areas [1]. In physiological conditions osteoclast (OC) and osteoblast activity is well balanced, but in pathologic condition this equilibrium (bone homeostasis) is disrupted. The role of OCs in osteolytic metastases has been clearly demonstrated, and it has been suggested that OCs might play an important role in the osteoblastic metastases as well. Interactions among CaP cells, osteoblasts and OCs suggest that bone tropism might be caused by tumour dependence on one or more osteoblast/OC-derived factors for cancer cell growth and maintenance [3].
###end p 11
###begin p 12
###xml 249 252 249 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato1">[4]</xref>
###xml 361 364 361 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Zhang1">[5]</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
We previously demonstrated that patients with osteolytic bone metastases from different solid tumours showed enhanced spontaneous osteoclastogenesis, due to increased T cell release of pro-osteoclastogenic factors, such as TNF-alpha, IL-7 and RANKL [4]. The role of OPG/RANKL axis in the osteolytic component of CaP-mediated bone metastases has been elucidated [5], while TNF-alpha and IL-7 possible functions in CaP bone lesions remain unclear.
###end p 12
###begin p 13
###xml 120 123 120 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Glass1">[6]</xref>
###xml 196 199 196 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Morvan1">[7]</xref>
###xml 475 478 475 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Li1">[8]</xref>
###xml 480 483 480 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Tian1">[9]</xref>
###xml 350 355 <span type="species:ncbi:9606">human</span>
Other key factors in bone biology are WNTs, a family of small secreted glycoproteins, which inhibits OC differentiation [6], stimulates osteoblastogenesis and mineralizing activity of osteoblasts [7]. The activity of WNT family is antagonized by several secreted factors such as dickkopf (DKK) proteins. Recent data reported DKK-1 expression in some human specimens of tumours, suggesting that a cancer-mediated modulation of WNT activity influences the metastatic phenotype [8], [9].
###end p 13
###begin p 14
###xml 250 258 <span type="species:ncbi:9606">patients</span>
This cross-sectional investigation was designed to study how bone forming metastases by CaP affects bone turnover, OC formation by peripheral blood mononuclear cells (PBMC), and the production of osteoclastogenic and anti-osteoclastogenic factors in patients affected by bone metastatic CaP.
###end p 14
###begin p 15
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
We report an increased osteoclastogenesis in CaP bone metastatic patients, due to an increase in the serum RANKL/OPG ratio, suggesting that enhanced OC formation plays an active role in bone forming metastases. We detected high DKK-1 serum levels and gene expression in CaP patients compared to healthy controls.
###end p 15
###begin title 16
Results
###end title 16
###begin title 17
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Bone turnover is increased in bone metastatic patients
###end title 17
###begin p 18
###xml 137 144 137 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003627-t001">Table 1</xref>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
The markers of bone turnover were higher in patients with bone metastases compared to non-bone metastatic patients and healthy controls (Table 1). In detail, CaP patients did not show significant differences in bone density, but had higher PTH, BAP, BGP, TRAPC5b and crosslink levels than healthy controls. These results confirm the disruption in bone homeostasis with increased bone resorption and formation in metastatic patients.
###end p 18
###begin title 19
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Characteristics of patients and healthy controls.
###end title 19
###begin p 20
###xml 247 248 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 266 267 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
Bone turnover marker values are shown as mean+/-SD, the p values were calculated by one way ANOVA and the Bonferroni post-hoc correction. * and degrees indicates the values significantly different between patients with/ without bone metastases (* p = 0.001, degrees p = 0.000).
###end p 20
###begin title 21
Osteoclastogenesis is increased in CaP bone metastases
###end title 21
###begin p 22
###xml 144 152 144 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
To evaluate whether the enhancement of bone resorption in metastatic patients is due to an increase in OC formation, we examined the ability of in vitro PBMCs to spontaneously differentiate in OCs in patients with or without bone metastases and in healthy controls.
###end p 22
###begin p 23
###xml 141 150 141 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003627-g001">Fig. 1A&#8211;C</xref>
###xml 166 173 166 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003627-g001">Fig. 1D</xref>
###xml 372 373 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 106 113 <span type="species:ncbi:9606">patient</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
The OC differentiation was demonstrated by the presence of multinucleated/TRAP positive cells from cancer patient and healthy control PBMCs (Fig. 1A-C). As showed in Fig. 1D the number of OCs was significantly higher in bone metastatic patients (mean+/-se, 216.22+/-39.55) than in patients without bone metastases (112.71+/-14.76) and in healthy controls (73.55+/-11.69), p<0.001.
###end p 23
###begin title 24
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Analysis of osteoclastogenesis from CaP patients' PBMCs.
###end title 24
###begin p 25
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
TRAP positive multinucleated cells were identified as OCs and counted, in both patients and healthy controls cultures, (A). The OC number in bone metastatic patients was significantly higher than in non-bone metastatic patients, p<0.004 and in healthy controls, p<0.001 (B).
###end p 25
###begin title 26
###xml 43 51 <span type="species:ncbi:9606">patients</span>
RANKL/OPG ratio is increased in metastatic patients
###end title 26
###begin p 27
###xml 438 439 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 380 388 <span type="species:ncbi:9606">patients</span>
In order to investigate the factors responsible for the increased osteoclastogenesis in patients, we dosed the serum levels of TNF-alpha, RANKL and OPG. The TNF-alpha serum levels were not significantly different among the three groups (data not shown), while we observed a significantly increased ratio RANKL/OPG in bone metastatic sera (19.62+/-6.52) compared to non-metastatic patients (5.48+/-2.48) and healthy controls (6.89+/-2.6), p<0.03.
###end p 27
###begin title 28
###xml 40 48 <span type="species:ncbi:9606">patients</span>
IL-7 serum level is increased in cancer patients
###end title 28
###begin p 29
###xml 343 350 333 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003627-g002">Fig. 2A</xref>
###xml 647 654 637 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003627-g002">Fig. 2B</xref>
###xml 793 796 783 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato1">[4]</xref>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 616 624 <span type="species:ncbi:9606">patients</span>
We measured IL-7 serum levels in patients and controls. Serum IL-7 levels were significantly higher in bone metastatic patients (mean+/-se, 19.86+/-2.01 pg/ml) than in healthy controls (7.07+/-1.27 pg/ml), p<0.001. We dosed comparable IL-7 levels in non-bone metastatic (19.75+/-3.55 pg/ml) and bone metastatic patients (19.86+/-2.01 pg/ml), (Fig. 2A). This result led us to investigate whether tumor cells were responsible for the increase of IL-7 production; therefore we examined the quantitative IL-7 expression in CaP and in healthy prostate tissues. Tumour cells expressed low and comparable levels of IL-7 in patients and healthy controls (Fig. 2B). This suggests that the increased circulating IL-7 might depend on the production by the immune system cell, such as T and B lymphocytes [4].
###end p 29
###begin title 30
IL-7 expression by CaP.
###end title 30
###begin p 31
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
IL-7 serum levels in patients with/without bone metastases and in healthy controls were measured by ELISA. Bone metastatic (p<0.01) and non-bone metastatic patients (p<0.03) had significantly higher IL-7 serum levels compared to healthy controls (A). CaP and healthy tissues were analyzed by Real-Time PCR in order to quantify IL-7 gene expression. The IL-7 quantization was expressed as IL-7 on beta-Actin (the control gene) plasmid copy number. The histogram showed comparable IL-7 expression levels in CaP and healthy tissues.
###end p 31
###begin title 32
###xml 34 42 <span type="species:ncbi:9606">patients</span>
DKK-1 expression is higher in CaP patients
###end title 32
###begin p 33
###xml 68 71 68 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Li1">[8]</xref>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 210 217 210 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003627-g003">Fig. 3A</xref>
###xml 451 458 451 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003627-g003">Fig. 3B</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Literature data reported that DKK-1 is involved in bone homeostasis [8]. We dosed DKK-1 serum level in CaP patients and healthy controls. CaP patients showed higher DKK-1 levels than healthy controls, p<0.004 (Fig. 3A). To evaluate whether or not DKK-1 is produced by cancer tissues, we studied its expression on CaP and healthy tissues by RQ-PCR. Our data demonstrated that CaP tissue expressed significantly more DKK-1 than healthy tissue, p<0.001 (Fig. 3B).
###end p 33
###begin title 34
###xml 34 42 <span type="species:ncbi:9606">patients</span>
DKK-1 expression is higher in CaP patients.
###end title 34
###begin p 35
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 533 534 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
DKK-1 levels were dosed in serum patients with/without bone metastases and in healthy controls by ELISA. Bone metastatic (p<0.004) and non-bone metastatic patients (p<0.01) had significantly higher DKK-1 serum levels compared to healthy controls (A). CaP and healthy tissues were analyzed by Real-Time PCR in order to quantify DKK-1gene expression. The DKK-1 quantization was expressed as DKK-1 on beta-Actin (the control gene) plasmid copy number. The histogram showed higher DKK-1 expression levels in CaP than in healthy tissues, p<0.001 (B).
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Keller2">[10]</xref>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
Prostate cancer frequently develop bone forming metastases; nonetheless a brisk osteolytic activity is present in metastatic compared to non-metastatic patients [10]. The mechanisms through which CaP promotes aberrant bone remodelling are not clearly defined. The disclosure of tumour nesting in bone might provide new tools for an early diagnosis of bone metastases and suggest novel therapeutic regimens for the control of CaP progression. The aim of our study was to investigate how the osteolytic component of bone metastasis affects bone turnover, OC formation by PBMC, and the production of osteoclastogenic and anti-osteoclastogenic factors in patients affected by bone metastatic CaP.
###end p 37
###begin p 38
###xml 387 390 387 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Logothetis1">[3]</xref>
###xml 487 491 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Jacobs1">[11]</xref>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 242 250 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
In the selection of CaP cases, we decided to avoid patients with an advanced metastatic disease, since therapeutic regimens might represent a bias for our analysis. In this study, we have an imbalance between the bone and non-bone metastatic patients' number, which depends on the presence of a smaller amount of bone metastatic compared to non-bone metastatic CaP patients at diagnosis [3]. In fact, in the natural history of the disease, bone metastases are a frequent, but late event [11].
###end p 38
###begin p 39
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Schwartz1">[12]</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
The bone turnover was enhanced in bone metastatic patients, in particular we observed both an increase in bone formation and resorption markers. PTH level was slightly increased in bone metastatic patients compared to healthy controls, according to PTH ability to promote the growth and invasiveness of prostate cancer cells in bone [12].
###end p 39
###begin p 40
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato2">[13]</xref>
###xml 225 233 225 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Lau1">[14]</xref>
###xml 882 886 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Corey1">[15]</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
The observed increase in bone resorption and the previously demonstrated spontaneous osteoclastogenesis in cancer patients with osteolytic metastases [13] prompted us to investigate osteoclastogenesis from CaP patients' PBMC in vitro. OC formation was higher in bone metastatic patients compared to both non-bone metastatic patients and healthy controls. To identify the factors responsible for the increase in OC formation, we measured molecules mostly involved in osteoclastogenesis, such as TNF-alpha, RANKL, OPG, IL-7 and DKK-1. The TNF-alpha serum levels were not significantly increased in CaP patients, differently from other bone metastatic tumours, where TNF-alpha plays an important role in osteoclastogenesis [14]. Otherwise the RANKL/OPG ratio was higher in bone metastatic patients, explaining the increased osteoclastogenesis and according to previous literature data [15].
###end p 40
###begin p 41
###xml 212 215 212 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato1">[4]</xref>
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-AlRawi1">[16]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Giuliani1">[17]</xref>
###xml 752 756 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato3">[18]</xref>
###xml 1193 1196 1193 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato1">[4]</xref>
###xml 1198 1202 1198 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Colucci1">[19]</xref>
###xml 1204 1208 1204 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-DAmelio1">[20]</xref>
###xml 1307 1310 1307 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Glass1">[6]</xref>
###xml 1383 1386 1383 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Morvan1">[7]</xref>
###xml 1464 1468 1464 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Emami1">[21]</xref>
###xml 1525 1529 1525 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Levasseur1">[22]</xref>
###xml 1628 1632 1628 1632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-VoorzangerRousselot1">[23]</xref>
###xml 1787 1790 1787 1790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Li1">[8]</xref>
###xml 1797 1802 1797 1802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 2021 2025 2021 2025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Hall1">[24]</xref>
###xml 2220 2223 2220 2223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Li1">[8]</xref>
###xml 3056 3060 3056 3060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-VoorzangerRousselot1">[23]</xref>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 2057 2065 <span type="species:ncbi:9606">patients</span>
###xml 2304 2312 <span type="species:ncbi:9606">patients</span>
###xml 2423 2431 <span type="species:ncbi:9606">patients</span>
###xml 2738 2746 <span type="species:ncbi:9606">patients</span>
###xml 2817 2825 <span type="species:ncbi:9606">patients</span>
###xml 2914 2922 <span type="species:ncbi:9606">patients</span>
###xml 2960 2968 <span type="species:ncbi:9606">patients</span>
The interplay among the tumour cells, the immune system and the bone tissue has become a relevant object of intensive study. Since IL-7 involvement in bone metastasis was previously demonstrated in other tumours [4], [16], we investigated this issue showing an increase in serum IL-7 levels in CaP patients with and without bone lesions. The increase of IL-7 might account for the RANKL/OPG augment, since IL-7 stimulates RANKL production from T cells [17]. We evaluated IL-7 gene expression in CaP and normal prostate tissues, showing comparable IL-7 expression in prostate cancer and normal tissues. This result differs from our published data on lung cancer, where the tumour tissue expressed higher IL-7 levels compared with the normal counterpart [18]. We suggest that this discrepancy might be due to the different tumour type and bone metastatic behaviour, as lung cancer causes osteolytic metastases, while CaP produces mainly bone forming lesions. The increased IL-7 serum level may depend on immune system activation against the tumour. In fact, it has been previously demonstrated that T and B cells produce IL-7, in both tumours and other pathologies associated to bone resorption [4], [19], [20]. WNT signalling plays an important role in bone development, since it inhibits OC differentiation [6], stimulates osteoblastogenesis and mineralizing activity of osteoblasts [7]. WNT proteins are also expressed by CaP and can promote tumour bone invasion [21]. DKK is a soluble inhibitor of canonical WNT signalling [22]. A recent study associates DKK-1 expression in breast cancer with the presence of bone metastases [23]. Data regarding DKK-1 expression in CaP are scant: some authors report an increase DKK-1 expression in osteolytic lesions, but not in the primary tumours [8]. Hall et al reported that CaP-derived DKK-1 is involved in osteoblastic activity in bone metastases, since DKK-1 signalling might account for switching the bone response to CaP cells from osteolytic to osteoblastic and vice versa [24]. In this work, we studied only patients with bone forming metastases, therefore we are unable to correlate osteolytic activity induced by CaP cells and DKK-1 expression, as previously described [8]. Nonetheless, we found a large amount of DKK-1 in serologic samples from cancer patients and an enhanced DKK-1 gene expression in CaP tissues, suggesting that the increased serum DKK-1 levels in CaP patients might depend on the CaP cell secretion. This result will be deeply study in order to evaluate the potential role of DKK-1 as tumour marker in CaP. Moreover, we could speculate that CaP cells stimulate bone marrow environment to increase the DKK-1 release through unknown mechanisms. In our bone metastatic patients, serum DKK-1 levels are slightly increased compared to non-metastatic patients, without a statistically significant difference. This could depend on our low number of patients, but investigating a large number of patients, we expect to show a difference between the two groups, confirming the literature data [23].
###end p 41
###begin title 42
Materials and Methods
###end title 42
###begin title 43
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and markers of bone turnover
###end title 43
###begin p 44
###xml 633 637 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-DAmelio2">[25]</xref>
###xml 1307 1309 1307 1309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">99</sup>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 465 468 <span type="species:ncbi:9606">men</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 829 837 <span type="species:ncbi:9606">Patients</span>
###xml 1038 1046 <span type="species:ncbi:9606">patients</span>
The experimental project and all the studies performed on the patients were approved by the Ethical Committee of our Institution (Azienda Ospedaliera-Universitaria San Giovanni Battista in Torino) and written informed consent from patients and healthy controls was obtained. The studied population included 46 patients affected by newly diagnosed CaP (37 had a primary tumour only, while 9 had primary tumour and concomitant bone forming metastases) and 20 healthy men. In all patients there was no evidence of metastasis to other non-bone sites. It has been demonstrated that estrogen loss significantly affect osteoclast formation [25]. Thus we studied CaP that, being an only male tumour, avoids by default all the possible biases due to the cyclical estrogen variations and postmenopausal fall in estrogen levels in females. Patients and controls were matched for age and body mass index. Bone mineral density (BMD) was measured by double-emission X-ray absorptiometry with a Hologic QDR 4500 at lumbar spine and femoral neck both in patients and controls. Subjects with intestinal malabsorption diseases, other kind of deficient nutritional status, secondary osteoporosis or taking drugs active on bone turnover or anti cancer therapy were excluded. The presence of bone metastases was confirmed using 99Tc bone scanning and further imaging studies according to the standard clinical practice.
###end p 44
###begin p 45
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Brown1">[26]</xref>
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Mancini1">[27]</xref>
###xml 474 478 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Ebert1">[28]</xref>
###xml 583 587 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Halleen1">[29]</xref>
###xml 790 794 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Killian1">[30]</xref>
###xml 796 800 796 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Gleason1">[31]</xref>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 758 766 <span type="species:ncbi:9606">patients</span>
In order to investigate bone metabolism status, patients and controls were subjected to analysis of standard clinical markers of bone metabolism, such as serum PTH, bone alkaline phosphatase (BAP), calcium, phosphate, osteocalcin (BGP) and urinary deoxypyridinoline (urinary crosslinks) [26]. In particular, crosslinks dosage has been chosen in clinical practice to monitor bone metastatic disease and the response to anti-resorbing treatments such as bisphosphonates [27], [28]. As markers of bone resorption we also measured Tartrate Resistent Acid Phosphatase 5b (TRAP5b) in sera [29], by BoneTRAP ELISA kit (Suomen Bioanalytiikka Oy, Turku, Fin). Serological markers, such as PSA and histological grading, according to Gleason, were recorded for all the patients included in this study [30], [31]. All biochemical measurements were performed on a single blood or urinary sample at a single time point per subject.
###end p 45
###begin title 46
Cell cultures
###end title 46
###begin p 47
###xml 24 28 24 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato2">[13]</xref>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
As previously described [13], for all patients and healthy controls, PBMCs were isolated from peripheral blood and cultured in alpha-MEM, supplemented with 10% FBS, penicillin 100 U/ml and streptomycin 100 microg/m (Cambrex, Bio Science, Walkersville, MD), without adding exogenous stimulatory factors such as M-CSF and RANKL. After 15 days, cultures were stopped, mature OCs were identified as multinucleated cells containing three or more nuclei and positive for TRAP expression (Sigma Aldrich, St. Louis, MO).
###end p 47
###begin title 48
Cytokines dosage
###end title 48
###begin p 49
In order to evaluate factors involved in osteoclastogenesis the amount of serum total RANKL (free and OPG-bound), OPG, TNF-alpha, IL-7 and DKK-1 were determined by commercially available ELISA kit according to manufacturer's instructions. Samples were assayed in duplicate and data were expressed as mean values. The sensitivities were: 1.56 to 30000 pg/ml for total RANKL (Apotech Corporation, Epalinges, CH); 0 to 4000 pg/ml for OPG; 0.12 to 32 pg/ml for TNF-alpha; 0.1 to 16 pg/ml for IL-7 (R&D system, Abingdon, UK) and 0.38 to 50 pmol/L for DKK-1 (Biomedica, Wien, A).
###end p 49
###begin title 50
RNA extraction from formalin-fixed, paraffin-embedded (FFPE) CaP tissues
###end title 50
###begin p 51
###xml 59 67 <span type="species:ncbi:9606">patients</span>
We extracted RNA from FFPE CaP and healthy tissues. For 19 patients, we obtained samples from tumour and healthy tissue blocks, the tumour areas were selected on the haematoxylin/eosin sections by microscope and manually dissected. RNA was isolated from FFPE CaP tissue block (10 microm sections) using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Huntingdon, UK). 1 microg of RNA was converted up to single stranded cDNA by the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Warrington, UK).
###end p 51
###begin title 52
###xml 14 21 <span type="species:ncbi:9606">patient</span>
Generation of patient plasmid standard
###end title 52
###begin p 53
###xml 208 212 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato3">[18]</xref>
###xml 252 274 246 268 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGAAGCGCCGAAAACG-3&#8242;</named-content>
###xml 289 320 283 314 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACACACATATTCCATTTTTGCAGTA-3&#8242;</named-content>
###xml 517 521 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato3">[18]</xref>
###xml 847 850 828 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">260</sub>
PCR primers for IL-7, DKK-1 and beta-Actin were designed using Primer Express v2.0 software and synthesized by Applied Biosystems (Warrington, UK). The IL-7 and beta-Actin sequences were previously published [18], while the DKK-1 sequences were: sense 5'-GGAAGCGCCGAAAACG-3' and antisense 5'-ACACACATATTCCATTTTTGCAGTA-3'. Purified fresh PCR products of 80-bp for IL-7, 75-bp for DKK-1 and 78-bp for beta-Actin were directly cloned using TA Cloning Kit Dual Promoter (Invitrogen, Carlsbad, CA) as previously described [18]. Positive clones were sequenced to confirm their identity. 10 microg of the selected plasmid for the genes were digested with 8 U of Hind III restriction enzyme overnight at 37degreesC. Linearized plasmids were finally purified with NucleoSpin clean up extraction kit (Macherey-Nagel, Duren, D), resuspended with 1x TE and OD260 was determined. Copy number was calculated from the plasmid concentration, mean molecular weight of the nucleotides (660 g/Mol) and plasmid plus insert length.
###end p 53
###begin title 54
Real-Time Quantitative analysis of IL-7 and DKK-1 gene expression
###end title 54
###begin p 55
###xml 632 636 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003627-Roato3">[18]</xref>
###xml 665 693 650 678 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATGCGTCACGCTATGTGCTGCC-3&#8242;</named-content>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Considering the higher amount of serum IL-7 and DKK-1 in CaP patients both with and without bone metastases, we decided to investigate whether these factors are produced by tumor cells. We performed quantitative analysis of IL-7 and DKK-1 expression by Real-Time Quantitative PCR (RQ-PCR), beta-Actin was the housekeeping control. RQ-PCR analysis of IL-7 and DKK-1 was carried out using the iCycler iQtrade mark system (Bio Rad, Hercules, CA, USA). TaqMan probes were designed using Primer Express v2.0 software and synthesized by Applied Biosystems (Warrington, UK). IL-7 and beta-Actin specific TaqMan probes were previously used [18], while the DKK-1 probe was (5'-ATGCGTCACGCTATGTGCTGCC-3'). All the probes were labelled at the 5' end with 6-carboxy fluorescein (FAM) and the 3' end with 6-carboxy-tetrametil rhodamine (TAMRA). Reactions for IL-7, DKK-1 and beta-Actin quantification were performed in a 25 microl final volume with 2 microl of sample cDNA, 1x iQ Supermix (Bio Rad, Hercules, CA, USA), 0,3 microM of each primer and 0,4 microM of the probes. PCR primers were the same used for IL-7, DKK-1 and beta-Actin cloning. The amplification conditions for quantization were: 95degreesC for 15 minutes, 50 cycles at 95degreesC for 15 seconds, 58degreesC for IL-7, 60degreesC for DKK-1 and beta-Actin for 1 minute.
###end p 55
###begin title 56
Statistical analyses
###end title 56
###begin p 57
###xml 710 711 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
Statistical analyses were performed by the Statistical Package for the Social Sciences (spssx/pc) software 15.0 (SPSS, Chicago, IL, USA). Continuous variables were expressed as mean and standard deviation. In order to compare patients both with and without bone metastases and controls, we performed a one way analysis of variance (ANOVA). Bonferroni correction was carried out for multiple comparisons. To explore the effect of the continuous variables analysed on OC formation, we fitted a linear regression model by step way procedure. The gene expression of DKK-1 and IL-7 was compared between tumour and healthy tissue by paired Student's T test. The results were considered statistically significant for p<0.05.
###end p 57
###begin p 58
We thank Raffaele Troiano for technical assistance.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
Prostate carcinoma skeletal metastases: cross-talk between tumor and bone.
###end article-title 60
###begin article-title 61
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
###end article-title 61
###begin article-title 62
Osteoblasts in prostate cancer metastasis to bone.
###end article-title 62
###begin article-title 63
###xml 60 68 <span type="species:ncbi:9606">patients</span>
IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor.
###end article-title 63
###begin article-title 64
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.
###end article-title 64
###begin article-title 65
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
###end article-title 65
###begin article-title 66
Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.
###end article-title 66
###begin article-title 67
Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
###end article-title 67
###begin article-title 68
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
###end article-title 68
###begin article-title 69
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
###end article-title 69
###begin article-title 70
Spread of prostatic cancer to bone.
###end article-title 70
###begin article-title 71
Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases.
###end article-title 71
###begin article-title 72
Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement.
###end article-title 72
###begin article-title 73
Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma.
###end article-title 73
###begin article-title 74
Osteoprotegerin in prostate cancer bone metastasis.
###end article-title 74
###begin article-title 75
###xml 69 74 <span type="species:ncbi:9606">human</span>
Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours.
###end article-title 75
###begin article-title 76
###xml 44 49 <span type="species:ncbi:9606">human</span>
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.
###end article-title 76
###begin article-title 77
Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer.
###end article-title 77
###begin article-title 78
###xml 138 143 <span type="species:ncbi:9606">human</span>
Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis.
###end article-title 78
###begin article-title 79
###xml 89 95 <span type="species:ncbi:9606">humans</span>
Immune system and bone metabolism: Does thymectomy influence postmenopausal bone loss in humans?
###end article-title 79
###begin article-title 80
When prostate cancer meets bone: control by wnts.
###end article-title 80
###begin article-title 81
LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
###end article-title 81
###begin article-title 82
Increased Dickkopf-1 expression in breast cancer bone metastases.
###end article-title 82
###begin article-title 83
Prostate cancer cells promote osteoblastic bone metastases through Wnts.
###end article-title 83
###begin article-title 84
Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis.
###end article-title 84
###begin article-title 85
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
###end article-title 85
###begin article-title 86
Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.
###end article-title 86
###begin article-title 87
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
###end article-title 87
###begin article-title 88
Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption.
###end article-title 88
###begin article-title 89
Prostate-specific antigen: questions often asked.
###end article-title 89
###begin p 90
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 90
###begin p 91
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by Compagnia di San Paolo and Regione Piemonte (Ricerca Sanitaria Finalizzata 2008).
###end p 91

